Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle Sells 4,949 Shares

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Kura Oncology Stock Performance

Kura Oncology stock traded down $0.14 during midday trading on Tuesday, hitting $7.77. The stock had a trading volume of 1,544,944 shares, compared to its average volume of 1,497,249. The firm’s fifty day moving average is $9.23 and its two-hundred day moving average is $15.69. The company has a market capitalization of $604.20 million, a PE ratio of -3.29 and a beta of 0.81. Kura Oncology, Inc. has a 52-week low of $6.98 and a 52-week high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the previous year, the business earned ($0.50) EPS. On average, research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on KURA. Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. HC Wainwright upped their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, November 21st. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in shares of Kura Oncology during the third quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after acquiring an additional 1,750 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology in the third quarter valued at approximately $146,000. Quarry LP purchased a new stake in shares of Kura Oncology during the second quarter worth approximately $196,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology during the third quarter worth approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.